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Abstract- Large preterm infants are generally not considered good candidates for surfactant treatment 
until they have been intubated for progressing respiratory distress. This study has been done to detect 
the effect of electively providing early single-dose surfactant to large preterm babies with mild to 
moderate respiratory distress syndrome (RDS). A randomized clinical trial was performed on 45 infants 
with birth weight > 1250 grams, gestational age < 36 weeks, postnatal age 0-12 hours, FiO2 > 40% and 
no immediate need for intubation. They were randomly divided into two interventional (n = 22) and 
control (n = 23) groups. Interventional group infants were intubated and received surfactant in the first 
12 hours of life with signs of mild to moderate RDS and were extubated as soon as possible. The 
control group infants were only intubated and received surfactant when clinically or radiographically 
indicated. The primary outcome was duration of assisted ventilation. Interventional group infants had a 
median duration of assisted ventilation of 4.45 hours compared to 1.02 hours in the control group in the 
first 24 hours of life, since only 8 of 23 infants in the control group (34%) needed intubation and 
mechanical ventilation. There were no differences in the two groups for need of subsequent retreatment 
with surfactant and requirement for supplemental oxygen or mechanical ventilation, hospital stay and 
adverse outcomes. Results of this study indicate that elective intubation for administration of early 
single-dose surfactant to large preterm infants is not necessary. 
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All regimens of surfactant administration for 
prophylaxis or treatment of neonatal respiratory 
distress syndrome had shown a major impact in 
reducing the morbidity and mortality rates from the 
disease (1). The safety and efficacy of exogenous 
surfactant have been clearly established (2). Meta 
analyses  demonstrated  that,  compared  to  selective   
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administration, prophylactic administration of 
natural surfactant to infants less than 30 weeks of 
gestation resulted in a greater reduction in neonatal 
mortality and a reduction in the combined outcome 
of bronchopulmonary dysplasia or death (3).  
Since surfactant is administered through an 
endotracheal tube and intubation has its own 
complications, large preterm infants are generally 
not considered good candidates for surfactant 
treatment until they have been intubated for 
progressing respiratory distress (2). At what point do 
the potential benefits of decreased mortality, 
pneumothorax, and lung injury from prophylactic 
surfactant exceed the potential risks of endotracheal 
intubation and the costs of surfactant dosing to 
infants who would not have required it is not known. 
Early surfactant for large infants 
Although nasal continuous positive pressure (CPAP) 
and supplemental oxygen often suffice for 
respiratory distress syndrome (RDS) treatment in 
larger infants, some may require mechanical 
ventilation. 
Few studies have been done about the reduced 
need of intubation and ventilator support after single 
dose of surfactant administration in large infants. 
Verder et al. randomly assigned 73 non-ventilated 
large preterm infants to surfactant prophylaxis 
followed by nasal CPAP or CPAP alone and 
reported a reduction in proportion of infants who 
were subsequently intubated (43% vs 85%). There 
was no difference in median length of ventilation or 
oxygen therapy (1). Based on the only differences 
reported in that study, the early treatment strategy 
would require intubating 2.4 infants for early 
surfactant to avoid intubating one infant later on. 
Systematic early intubation would expose more 
infants to additional risks of airway complications 
and there are some concerns of pulmonary air leaks 
and intracranial hemorrhage (4). So we need more 
information to justify the routine administration of 
surfactant to large preterm infants with mild to 
moderate RDS. 
This clinical trial has been performed in two 
NICUs in Tehran to determine the effect of early 
surfactant administration in large preterm infants. 
 
MATERIALS AND METHODS 
 
This was a randomized clinical trial designed to 
evaluate the efficacy and safety of elective brief 
intubation for early single-dose surfactant 
administration in large preterm infants with mild to 
moderate RDS. The study was approved by Ethics 
Committee of Iran University of Medical Sciences 
and written informed consent was obtained from 
parents of all subjects. 
Eligibility criteria included birth weight > 1250 
grams, gestational age < 36 weeks, postnatal age 0-
12 hours, FiO2 > 40%, clinical presentation or chest 
radiograph consistent with RDS, no requirement for  
mechanical ventilation (by the written protocols of 
the ward), no known congenital anomalies of the 
cardiac or respiratory system. 
Forty–five infants were randomly divided into 
two groups; interventional (n = 22) and control (n = 
23). Interventional group infants were intubated and 
received surfactant (4 mL/kg  Survanta) in the first 
12 hours of birth and they were extubated as soon as 
possible unless their FiO2 remained greater than 
before intubation. In these cases mechanical 
ventilation was provided according to ward protocols. 
Control group infants were given surfactant when 
they met the usual criteria of the ward for intubation. 
Median duration of assisted ventilation, oxygen 
therapy, need for retreatment with surfactant and 




Forty-five infants were enrolled from September 
2004 to August 2005. Their demographic data are 
shown in Table 1. There were no significant 
differences between two groups. 
Duration of mechanical ventilation was 4.45 
hours (range 2-8 h) in interventional group as 
compared to 1.02 hours in the  control group (P = 
0.005) in the first 24 hours.  The other parameters 
between the two groups were not statistically 
different (Table 2). Of 22 infants in the 
interventional group, 8 (36.3%) required subsequent 
mechanical ventilation for worsening respiratory 
distress and in the control group 8 infants needed 
mechanical ventilation as well (34.7%), (P = 0.93). 
Two infants in each group needed additional dose of 
surfactant in the second day of life due to their high 
ventilator needs. There was no significant difference 
in adverse outcomes (air leak, pulmonary 
hemorrhage, and PDA). There were 2 deaths in each 
group due to severe sepsis and DIC. 
 






Birth weight (g)†  1642.1 ± 226 1695.9 ± 222 
Birth weight (g)  
  1250-1500 
  1500-1750 









Gestational age (wk) † 31.8 ± 2 31.3 ± 1.9 
Sex (male/female) 14:9 12:10 
Antenatal steroid 7 8 
Route of delivery (V/CS) 9:14 7:15 
Abbreviations: V, vaginal; CS, Cesarian section.  
*Data are given as number unless specified otherwise. 
†Mean ± SD. 
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Table 2. Outcome data* 
Outcome Control (n = 23) Intervention (n = 22) P value 
Duration of assisted ventilation (h) in the first 24 hours† 1.02 ± 0.8 (0-3) 4.45 ± 1.7 (2-8) 0.005 
Duration of oxygen therapy (d) 5.17 ± 2.28 (4.3-7.5) 6.1 ± 3(3.8-8) 0.38 
Length of hospital stay (d) 20 (13-32) 19 (11-33) 0.95 
Air leak 4/23 3/22 1.33(0.26-6.78) 
Pulmonary hemorrhage 1/23 1/22 0.95 (0.56-16.2) 
Treated PDA 3/23 2/22 1.5 (0.2-9.9) 
IVH grade II-IV 2/23 3/22 0.6 (0.9-4) 
Death 2/23 2/22 0.95 (0.17-5.3) 
Mechanical ventilation 8/23 8/22 0.93 (0.27-3.1) 
Abbreviations: PDA, patent ductus arteriosus; IVH, intraventricular hemorrhage.  
*Data are given as number unless specified otherwise. 





The first successful surfactant therapy in humans 
was reported by Fujiwara and colleagues in 1980. 
Natural and synthetic surfactant has been 
successfully administered into the lungs of 
premature infants for treatment of RDS as 
prophylactic or rescue therapies (5, 6). All regimens 
of surfactant therapy appear to decrease the 
incidence of air leaks, and improve oxygenation of 
ventilated infants. More strikingly mortality from 
RDS and even overall mortality of ventilated 
preterm infants is significantly reduced. 
Early rescue surfactant administration (within 2 
hours of birth) given to infants with RDS requiring 
mechanical ventilation leads to decreased risk of 
pneumothorax and pulmonary interstitial emphysema 
and chronic lung disease (7). Furthermore this 
strategy seems to reduce the need for subsequent 
retreatment and mechanical ventilation. 
In larger preterm babies, the course of disease 
may not be evident from the first hour of life and 
usually surfactant is administered to them when RDS 
is clinically or radiographically proven (8). Does 
earlier surfactant administration to these large 
preterm infants with mild to moderate RDS show to 
be beneficial? Victorian et al. performed a pilot 
study in Kuwait to determine if a single dose of 
surfactant would be useful in a situation in which 
mechanical ventilation was not universally available 
(2). There was a beneficial acute response in 12 of 
14 treated patients, but no longer-term outcomes 
were reported and there was no control group.  
As already noted, Verder et al. randomly 
assigned 73 neonates with moderate to severe RDS 
to a dose of surfactant followed by NCPAP (1). The 
need for subsequent mechanical ventilation was 
reduced, but there was no difference in total duration 
of mechanical ventilation or use of oxygen. 
In our study there was no difference between two 
groups (intervention or control) for need of 
subsequent retreatment with surfactant and 
requirement for supplemental oxygen and mechanical 
ventilation, hospital stay and adverse outcomes. 
 In summary, the results of our study do not 
support the routine use of intubation solely to 
administer surfactant in large preterm infants with 
mild to moderate RDS. 
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